Bisphosphonates and cancer

Journal of Veterinary Internal Medicine

Volumn 18, Issue 5, 2004, Pages 597-604

  Milner, Rowan J ^a   Farese, James ^a   Henry, Carolyn J ^b   Selting, Kim ^b   Fan, Timothy M ^c   De Lorimier, Louis Philippe ^c  

^a University of Florida College of Veterinary Medicine   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c Veterinary Teaching Hospital   (United States)

Author keywords

Adverse effects; Alendronate; Etidronate; Hypercalcemia of malignancy; Multiple myeloma; Osteosarcoma; Pamidronate; Zoledronate

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CISPLATIN; CLODRONIC ACID; CYTOKINE; ETIDRONIC ACID; GROWTH FACTOR; IBANDRONIC ACID; MATRIX METALLOPROTEINASE; MEVALONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ALLERGIC REACTION; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE METASTASIS; BONE PAIN; BONE REMODELING; CANCER; CANCER INHIBITION; CELL ACTIVITY; CELL ENERGY; CELL METABOLISM; CELL PROLIFERATION; CHEMISTRY; CLINICAL TRIAL; DOG; DOG DISEASE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; ENERGY METABOLISM; ENZYME INHIBITION; ESOPHAGITIS; GASTRITIS; GASTROINTESTINAL TOXICITY; HUMAN; HYPERCALCEMIA; IMMUNOMODULATION; IN VITRO STUDY; INTESTINE ABSORPTION; NEPHROTOXICITY; NONHUMAN; ONCOLOGY; OSTEOCLAST; OSTEOLYSIS; OSTEOSARCOMA; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; VETERINARY MEDICINE;

ANIMALS; ANTINEOPLASTIC AGENTS; DIPHOSPHONATES; DOG DISEASES; DOGS; NEOPLASMS;

CANIS FAMILIARIS;

EID: 6444220920     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2004)18<597:BAC>2.0.CO;2     Document Type: Review

References (84)

1. Lin JH. Bisphosphonates: A review of their pharmacokinetic properties. Bone 1996; 18:75-85.
2. Fleisch H, Russell RG, Bisaz S, et al. The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution. Calcif Tissue Res 1968;(Suppl):10-10a.
3. Fleisch H, Russell RG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 1966;212:901-903.
4. Mercadante S. Malignant bone pain: Pathophysiology and treatment. Pain 1997;69:1-18.
5. Bouchet LG, Bolch WE, Goddu SM, et al. Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions. J Nucl Med 2000;41:682-687.
6. Milner RJ, Dormehl I, Louw WK, Croft S. Targeted radiotherapy with Sm-153-EDTMP in nine cases of canine primary bone tumours. J S Afr Vet Assoc 1998;69:12-17.
7. Mashiba T, Turner CH, Hirano T, et al. Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in Beagle bone before occurrence of spontaneous fractures. Bone 2001;29:271-278.
8. Hirano T, Turner CH, Forwood MR, et al. Does suppression of bone turnover impair mechanical properties by allowing microdamage accumulation? Bone 2000;27:13-20.
9. Rivero DP, Skipor AK, Singh M, et al. Effect of disodium etidronate (EHDP) on bone ingrowth in a porous material. Clin Orthop 1987;215:279-286.
10. Flora L, Hassing GS, Cloyd GG, et al. The long-term skeletal effects of EHDP in dogs. Metab Bone Dis Relat Res 1981;3:289-300.
11. Tarvainen R, Arnala I, Nevalainen T, et al. Clodronate increases bone mineral density in young growing oophorectomized Beagles. Ann Chir Gynaecol 1995;84:304-308.
12. Rumbeiha WK, Fitzgerald SD, Kruger JM, et al. Use of pamidronate disodium to reduce cholecalciferol-induced toxicosis in dogs. Am J Vet Res 2000;61:9-13.
13. 3-induced toxicosis in dogs. Am J Vet Res 1999;60:1092-1097.
14. King LE, Grynpas MD, Tomlinson G, Vieth R. Pamidronate content and turnover in sternum, vertebral body, and iliac bones of dogs. Bone 1997;20:405-411.
15. Mochida Y, Bauer TW, Akisue T, Brown PR. Alendronate does not inhibit early bone apposition to hydroxyapatite-coated total joint implants: A preliminary study. J Bone Joint Surg Am 2002;84-A:226-235.
16. Frenkel SR, Jaffe WL, Valle CD, et al. The effect of alendronate (Fosamax) and implant surface on bone integration and remodeling in a canine model. J Biomed Mater Res 2001;58:645-650.
17. Mashiba T, Hirano T, Turner CH, et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000;15:613-620.
18. Wang X, Shanbhag AS, Rubash HE, Agrawal CM. Short-term effects of bisphosphonates on the biomechanical properties of canine bone. J Biomed Mater Res 1999;44:456-460.
19. Peter CP, Handt LK, Smith SM. Esophageal irritation due to alendronate sodium tablets: Possible mechanisms. Dig Dis Sci 1998;43:1998-2002.
20. Shanbhag AS, Hasselman CT, Rubash HE. The John Charnley Award. Inhibition of wear debris mediated osteolysis in a canine total hip arthroplasty model. Clin Orthop 1997;344:33-43.
21. Peter CP, Cook WO, Nunamaker DM, et al. Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res 1996;14:74-79.
22. Peter CP, Guy J, Shea M, et al. Long-term safety of the aminobisphosphonate alendronate in adult dogs. I. General safety and biomechanical properties of bone. J Pharmacol Exp Ther 1996;276:271-276.
23. Lin JH, Duggan DE, Chen IW, Ellsworth RL. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos 1991;19:926-932.
24. Mashiba T, Turner CH, Hirano T, et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in Beagles. Bone 2001;28:524-531.
25. Forwood MR, Burr DB, Takano Y, et al. Risedronate treatment does not increase microdamage in the canine femoral neck. Bone 1995;16:643-650.
26. Boyce RW, Paddock CL, Gleason JR, et al. The effects of risedronate on canine cancellous bone remodeling: Three-dimensional kinetic reconstruction of the remodeling site. J Bone Miner Res 1995;10:211-221.
27. Monier-Faugere MC, Geng Z, Paschalis EP, et al. Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized Beagle dogs: Effects on bone morphometry and mineral properties. J Bone Miner Res 1999;14:1768-1778.
28. Tomlin JL, Sturgeon C, Pead MJ, Muir P. Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs. Vet Rec 2000;147:129-132.
29. Fan TM, de Lorimier L-P. Bisphosphonates: Molecular mechanisms and therapeutic uses in veterinary oncology. 21st Annual American College of Veterinary Internal Medicine Forum, Charlotte, NC, 2003.
30. Chew DJ, Schenck PA, Jaeger JQ. Assessment and treatment of clinical cases with elusive disorders of hypercalcemia. 21st Annual American College of Veterinary Internal Medicine Forum, Charlotte, NC, 2003.
31. Vasilopulos RJ, Mackin A. Humoral hypercalcemia of malignancy: Diagnosis and treatment. Compend Cont Educ Pract Vet 2003; 25:129-136.
32. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002;4:30-34.
33. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88(Suppl 12):2961-2978.
34. Neves M, Gano L, Pereira N, et al. Synthesis, characterization and biodistribution of bisphosphonates Sm-153 complexes: Correlation with molecular modeling interaction studies. Nucl Med Biol 2002;29:329-338.
35. Neville-Webbe HL, Holen I, Coleman RE. The anti-tumour activity of bisphosphonates. Cancer Treat Rev 2002;28:305-319.
36. Michael WR, King WR, Wakim JM. Metabolism of disodium ethane-1-hydroxy-1,1-diphosphonate (disodium etidronate) in the rat, rabbit, dog and monkey. Toxicol Appl Pharmacol 1972;21:503-515.
37. Gertz BJ, Holland SD, Kline WF, et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995;58:288-298.
38. Dormehl IC, Louw WK, Schneeweiss FH, et al. Uptake of ethylenediamine tetramethylene phosphonic acid in normal bone after multiple applications. A non-human primate study. Arzneimittelforschung 1998;48:408-414.
39. Gertz BJ, Holland SD, Kline WF, et al. Clinical pharmacology of alendronate sodium. Osteoporos Int 1993;3(Suppl 3):S13-S16.
40. Bone HG, Adami S, Rizzoli R, et al. Weekly administration of alendronate: Rationale and plan for clinical assessment. Clin Ther 2000;22:15-28.
41. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000;12:1-12.
42. Diez-Perez A. Bisphosphonates. Maturitas 2002;43(Suppl 1): S19-S26.
43. Body JJ. Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer 2003;97(Suppl 3):859-865.
44. Manolagas SC. Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000;21:115-137.
45. Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci 2002;966:73-81.
46. Weinstein RS, Chen JR, Powers CC, et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 2002;109:1041-1048.
47. Ito M, Amizuka N, Nakajima T, Ozawa H. Ultrastructural and cytochemical studies on cell death of osteoclasts induced by bisphosphonate treatment. Bone 1999;25:447-452.
48. Halasy-Nagy JM, Rodan GA, Reszka AA. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 2001;29:553-559.
49. Giuliani N, Pedrazzoni M, Passeri G, Girasole G. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand J Rheumatol 1998;27:38-41.
50. Fromigue O, Body JJ. Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Invest 2002;25:539-546.
51. Adami S, Zamberlan N. Adverse effects of bisphosphonates. A comparative review. Drug Saf 1996;14:158-170.
52. Halasy-Nagy J, Rodan GA, Reszka AA. Keratinocyte model for bisphosphonate esophageal irritation: Inhibition of cell growth by combined inhibition of protein prenylation and sterol synthesis. J Bone Miner Res 1999;14(Suppl 1):S406.
53. Reszka AA, Halasy-Nagy J, Rodan GA. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 2001;59:193-202.
54. Monkkonen H, Tormalehto S, Asunmaa K, et al. Cellular uptake and metabolism of clodronate and its derivatives in Caco-2 cells: A possible correlation with bisphosphonate-induced gastrointestinal side-effects. Eur J Pharm Sci 2003;19:23-29.
55. Green JR, Seltenmeyer Y, Jaeggi KA, Widler L. Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol Toxicol 1997;80:225-230.
56. O'Sullivan TL, Akbari A, Cadnapaphornchai P. Acute renal failure associated with the administration of parenteral etidronate. Ren Fail 1994;16:767-773.
57. Berenson JR, Rosen L, Vescio R, et al. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 1997;37:285-290.
58. Tyrrell CJ, Collinson M, Madsen EL, et al. Intravenous pamidronate: Infusion rate and safety. Ann Oncol 1994;5(Suppl 7):S27-S29.
59. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000;15:2211-2221.
60. Senaratne SG, Mansi JL, Colston KW. The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. Br J Cancer 2002;86:1479-1486.
61. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62:6538-6544.
62. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-1061.
63. Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002; 8:1080-1084.
64. Heikkila P, Teronen O, Moilanen M, et al. Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anticancer Drugs 2002;13:245-254.
65. Teronen O, Heikkila P, Konttinen YT, et al. MMP inhibition and downregulation by bisphosphonates. Ann N Y Acad Sci 1999;878:453-465.
66. Green JR. Antitumor effects of bisphosphonates. Cancer 2003; 97(Suppl 3):840-847.
67. Cory S, Adams JM. The BCL-2 family: Regulators of the cellular life-or-death switch. Nature Rev: Cancer 2002;2(September): 647-656.
68. Kochevar DT, Kochevar J, Garrett L. Low level amplification of c-sis and c-myc in a spontaneous osteosarcoma model. Cancer Lett 1990;53:213-222.
69. Sonnemann J, Eckervogt V, Truckenbrod B, et al. The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs 2001;12:459-465.
70. Mackie PS, Fisher JL, Zhou H, Choong PF. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer 2001;84:951-958.
71. Frith JC, Monkkonen J, Blackburn GM, et al. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1997;12:1358-1367.
72. Endo N, Rutledge SJ, Opas EE, et al. Human protein tyrosine phosphatase-sigma: Alternative splicing and inhibition by bisphosphonates. J Bone Miner Res 1996;11:535-543.
73. Klenner T, Wingen F, Keppler BK, et al. Anticancer-agent-linked phosphonates with antiosteolytic and antineoplastic properties: A promising perspective in the treatment of bone-related malignancies? J Cancer Res Clin Oncol 1990;116:341-350.
74. Pool BL, Berger M, Schlehofer JR, Wingen F. In vivo and in vitro investigations on biological effects of aromatic bis-(2-chloroethyl)amino- bisphosphonic acids, new agents proposed for chemotherapy of bone tumors: Cytostatic activity in rat osteosarcoma; toxicity and genotoxicity in liver and bone marrow; mutagenicity in S. typhimurium. Invest New Drugs 1988;6:67-78.
75. Saarto T, Blomqvist C, Virkunen P, Elomaa II. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-Year results of a randomized controlled trail. J Clin Oncol 2001;19:10-17.
76. Derenne S, Amiot M, Barille S, et al. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 1999;14:2048-2056.
77. Mundy GR. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-593.
78. Body JJ, Mancini I. Bisphosphonates for cancer patients: Why, how, and when? Support Care Cancer 2002;10:399-407.
79. Adami S. Bisphosphonates in prostate carcinoma. Cancer 1997; 80(Suppl 8):1674-1679.
80. Body JJ, Bartl R, Burckhardt P, et al. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 1998;16:3890-3899.
81. Body JJ. Bisphosphonates in the treatment of metastatic breast cancer. J Mammary Gland Biol Neoplasia 2001;6:477-485.
82. Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C. The role of bisphosphonates in the treatment of painful metastatic bone disease: A review of phase III trials. Pain 1998;78:157-169.
83. Paterson AH. Should bisphosphonates be standard therapy for bone pain? Support Care Cancer 1997;5:200-204.
84. Diel IJ. Antitumour effects of bisphosphonates: First evidence and possible mechanisms. Drugs 2000;59:391-399.